Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Gut health boost: could probiotics help diabetic kidneys?

NCT ID NCT05674981

Disease control Sponsor: GenMont Biotech Incorporation Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a probiotic supplement containing two live bacteria strains could help people with diabetic kidney disease. Fifty adults with type 2 diabetes and early-stage kidney problems took either the probiotic or a placebo daily for 6 months. Researchers measured changes in kidney function and blood sugar levels to see if the probiotics could slow disease progression.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Probiotic supplement containing Lactobacillus reuteri ADR-1 and Lactobacillus rhamnosus GM-020
What this could lead to
If it works, this could point toward a simple, safe way to help manage diabetic kidney disease by improving gut health.
What could go wrong
This is a small, early-stage trial with only 50 participants. The results may not apply to everyone, and the benefit might be small or not clinically meaningful.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

50 people

The number who actually took part.

Started

Apr 2023

Finished

May 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

25 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age between 25 and 80 years old * Suffering from type 2 diabetes and stable medication for 3 months * Detection of HbA1c before meals between 7% and 10% * Stage 1-3a diabetic nephropathies (eGFR \> 45 mL/min) * Microalbuminuria estimated between 30 to 300 mg/day Exclusion Criteria: * Patients with Type I Diabetes Mellitus * Patients with inflammatory bowel disease, liver disease, liver cirrhosis, systemic lupus erythematosus, malignancy, and high blood pressure. * Patients with hypoglycemic coma, Diabetic ketoacidosis, hyperosmolar non-ketotic diabetic coma, or diabetes mellitus acute complications. * Acute infection medical history in past 3 month * Fasting blood glucose \>13.3 mmol/L * GPT\>100U/L (2.5 times than usual situation) * Vulnerable population (Including breeding or pregnant women, prisoner, aboriginal, disabled population) * Smoker or Alcoholic * Taking Antibiotics in past 1 month * Stably taking probiotics supplements in past 1 months (Yogurt or dairy products were excluded) * Taking immunosuppressive drug, angiotensin-converting enzyme inhibitors, or angiotensin receptor blockers in past 3 months

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetic kidney disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diabetic kidney disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetic kidney disease

Contacts and locations

Locations

  • Chung Shan Medical University Hospital

    Taichung, Taiwan, 402, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.